Structure’s oral GLP-1 data mark bullish year for obesity pills
The GLP-1 fight has moved from injectables to pills, and Structure Therapeutics Inc. is in the ring with phase III-ready aleniglipron. According to the Bay Area biotech, its oral once-daily glucagon-like peptide-1 (GLP-1) drug candidate, aleniglipron, demonstrated an absolute weight loss of “up to 39 pounds” in the 44-week Access II trial.
Opinion: Semaglutide is going off-patent in India. But will people who need it be able to get it?
Rules determining who gets access to semaglutide in India were written for different bodies with different cardiovascular risks.
GLP-1 Drugs Show Growing Promise for Afib Control
(MedPage Today) — For patients with obesity and atrial fibrillation (Afib), GLP-1 receptor agonist drugs may be the weight loss approach that better addresses their arrhythmia, observational data suggested.
People who came out of catheter ablation…
Hold GLP-1s Before Endoscopy? Clinical Trial Finds Retained Gastric Contents
(MedPage Today) — Patients on GLP-1 or GLP-1/GIP agonists had significant residual gastric volume (RGV) if the medication wasn’t held prior to upper endoscopy unless they were on a clear liquid diet the day before, the OCULUS randomized trial…
Unixell Biotech’s UX-GIP001 gains IND clearance for epilepsy
Shanghai Unixell Biotechnology Co. Ltd. has obtained IND clearance from the FDA for UX-GIP001, its iPSC-derived allogeneic cell therapy for focal epilepsy. A phase I study will evaluate UX-GIP001 in patients with drug-resistant epilepsy.
Structure Therapeutics reports more Phase 2 data for oral GLP-1
Structure Therapeutics has its much-anticipated oral GLP-1 data, and the results look to give the next-generation contender a chance against market incumbents Eli Lilly and Novo Nordisk.
The biotech said Monday …
GLP-1 receptor agonists linked to lower mortality for patients with brain metastases, T2DM
For patients with cancer and brain metastases (BM) and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with significantly lower all-cause mortality, according to a research letter published online March 11 in JAMA Network Open.
What happens when patients stop taking GLP-1 drugs? New study reveals real world insights
As the use of injectable GLP-1 drugs continues to rise, questions persist about what happens after patients stop taking them in real-world settings. A new Cleveland Clinic analysis of nearly 8,000 patients suggests that discontinuing semaglutide and tirzepatide, on average, does not lead to significant weight regain in clinical practice, as many patients later restart the original medication or try an alternative obesity treatment.
Persistence With GLP-1 Receptor Agonist Therapy Remains Low Among Those With Overweight, Obesity
THURSDAY, March 12, 2026 — Less than 25 percent of adults with overweight or obesity without diabetes remain on any glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment after 12 months, according to a research letter published online March…
Impurity in Some Compounded Tirzepatide ‘Potentially Dangerous,’ Eli Lilly Warns
(MedPage Today) — Compounded versions of tirzepatide (Mounjaro, Zepbound) containing vitamin B12 pose a potential safety risk to the public, Eli Lilly warned in an open letter on Thursday.
Following laboratory testing, the drugmaker said it uncovered…